Present results and future perspectives in optimizing chronic myeloid leukemia therapy

Haematologica. 2018 Jun;103(6):928-930. doi: 10.3324/haematol.2017.182022.

Authors

Angelo M Carella¹, Giuseppe Saglio², Xavier F Mahon³, Michael J Mauro⁴

Affiliations

¹ Hematology and BMT Unit, Ospedale Policlinico San Martino, Genova, Italy [email protected].
² Dipartimento di Scienze Cliniche e Biologiche Università di Torino and Ospedale Mauriziano di Torino, Italy.
³ Bergonié Cancer Institute, University of Bordeaux, France.
⁴ Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

No abstract available

Publication types

Review

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Disease Management
Drug Resistance, Neoplasm
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / etiology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
Molecular Targeted Therapy / adverse effects
Molecular Targeted Therapy / methods
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use
Retreatment
Treatment Outcome

Substances

Antineoplastic Agents
Protein Kinase Inhibitors